| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PRTK | Common Stock | Award | $0 | +67.5K | +17.99% | $0.00 | 443K | Aug 8, 2023 | Direct | F1 |
| transaction | PRTK | Common Stock | Sale | -$60.7K | -27.6K | -6.23% | $2.20 | 415K | Aug 9, 2023 | Direct | F2, F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Represents performance-based restricted stock units ("PRSUs") granted on March 30, 2021 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 8, 2023. |
| F2 | Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan adopted on May 26, 2021. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.19 to $2.21. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4. |